Vaccines - Brazil

Brazil

In Brazil, the Vaccines market is expected to witness a significant growth in revenue, reaching a projected value of US$1.88bn in 2024.
Furthermore, the market is anticipated to exhibit a robust compound annual growth rate (CAGR 2024-2029) of 0.21%, leading to a market volume of US$1.90bn by 2029.
When compared to other countries globally, United States is projected to generate the highest revenue in the Vaccines market, with an estimated value of US$29,120.00m in 2024.
Brazil's growing demand for vaccines is driven by its large population and the need to combat infectious diseases.

Key regions: Australia, Italy, France, South Korea, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for vaccines in Brazil has been steadily increasing in recent years.

Customer preferences: Brazil has a large population with a high incidence of infectious diseases, which has led to a growing awareness of the importance of vaccination. Additionally, the government has implemented a number of vaccination programs to combat various diseases, which has further increased demand for vaccines.

Trends in the market: One of the major trends in the Brazilian vaccine market is the increasing demand for combination vaccines, which offer protection against multiple diseases in a single shot. This is particularly important in Brazil, where there is a high incidence of diseases such as measles, mumps, and rubella. Another trend is the growing popularity of adult vaccines, particularly for diseases such as influenza and pneumococcal disease.

Local special circumstances: Brazil has a large public healthcare system, which provides free vaccines to the population. However, there is also a growing private healthcare sector, which is driving demand for higher-end vaccines. Additionally, Brazil has a large agricultural sector, which has led to a demand for animal vaccines.

Underlying macroeconomic factors: Brazil has experienced significant economic growth in recent years, which has led to an increase in healthcare spending. Additionally, the government has implemented a number of policies to improve access to healthcare, particularly in rural areas. However, there are also a number of challenges facing the Brazilian vaccine market, including a lack of infrastructure and a shortage of healthcare professionals.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.